Floatz logo

ty-9591

EGFR Activating Mutation

TYK Medicines, IncPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the EGFR Activating Mutation cohort.

Asset / SponsorPhaseRating
Carboplatin
Juntendo University
Phase 4BB
Osimertinib
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Gefetinib
Sichuan University
Phase 4BB
Famitinib
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Nivolumab
University of Washington
Phase 2B

View all 21 →

Same molecule, other indications

ty-9591 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
neoplastic meningitisDormant
B
Indicative ·
57 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →